Dr. Sardar Z Imam

Claim this profile

San Juan Oncology Associates

Studies Stomach Cancer
Studies Gastroesophageal Junction Adenocarcinoma
3 reported clinical trials
5 drugs studied

Area of expertise

1Stomach Cancer
Sardar Z Imam has run 2 trials for Stomach Cancer. Some of their research focus areas include:
metastatic
locally advanced
Stage IV
2Gastroesophageal Junction Adenocarcinoma
Sardar Z Imam has run 2 trials for Gastroesophageal Junction Adenocarcinoma. Some of their research focus areas include:
metastatic
locally advanced
Stage IV

Affiliated Hospitals

Image of trial facility.
San Juan Oncology Associates

Clinical Trials Sardar Z Imam is currently running

Image of trial facility.

Disitamab Vedotin + Tucatinib

for Breast Cancer

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting1 award Phase 26 criteria
Image of trial facility.

SEA-CD70

for Myelodysplastic Syndrome and Acute Myeloid Leukemia

This trial is testing a new drug, SEA-CD70, alone and with azacitidine, to see if it is safe and works for adults with certain blood cancers that haven't responded to other treatments. The study will determine the best dose and check for side effects. Azacitidine is a treatment that improves survival, reduces the need for transfusions, and lowers the risk of progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes.
Recruiting1 award Phase 110 criteria

More about Sardar Z Imam

Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Sardar Z Imam has experience with
  • Ladiratuzumab Vedotin
  • Pembrolizumab
  • SEA-CD70
  • Disitamab Vedotin
  • Tucatinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sardar Z Imam specialize in?
Is Sardar Z Imam currently recruiting for clinical trials?
Are there any treatments that Sardar Z Imam has studied deeply?
What is the best way to schedule an appointment with Sardar Z Imam?
What is the office address of Sardar Z Imam?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security